Latest Articlesddd
Positive Results of INGREZZA on Tardive Dyskinesia Highlights Neurocrine Biosciences Sciences and Scientists The results …
Everybody knows Bristol-Myers Squibb (BMY), but just a few may know anything about CytomX Therapeutics (CTMX), …
AMGEN Amgen’s (AMGN) cholesterol lowering drug Repatha is the only drug that has demonstrated protection against …
Nektar Therapeutics (NKTR) announced positive results from the SUMMIT-07 Phase 3 efficacy study of its painkiller …
OncoCyte (OCX) has news. This firm, which develops non-invasive blood and urine liquid biopsy diagnostic tests …
Prohost Letter #406 A Special Prohost Issue SYNOPSIS REASONS FOR THE FOLLOWING PROHOST PICKS RALLIES VERTEX …
Prohost Letter #405 Synthetic Biology (3) We have already decided upon becoming shareholders the day synthetic …
Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals (IONS), announced positive results from the pivotal …
A few days ago, the FDA approved Lexicon Pharmaceutical’s (LXRX) drug Xermelo™ (telotristat ethyl) 250 mg …
An approved rheumatoid arthritis drug developed and sold by Sanofi could become a new treatment for …
We keep reiterating that CAR-T cancer immunotherapy was created to stay. More frequent updates about the …
Exelixis (EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study of …
Incyte Announces a Multi-year Research Collaboration with the Abramson Cancer Center at the University of Pennsylvania. …
Making Sure that CAR-T Therapy for Cancer Succeeds Academic Researchers Identify a New Process to Raise …
Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore …
Watching the outperformance of the new approaches for cancer immunotherapies, especially the checkpoint inhibitors and other …
About the CRISPR/Cas9 Gene Editing Patent Shareholders of biotechnology firms specialized in CRISPR gene editing technology …
Immunomedics (IMMU) and Seattle Genetics (SGEN) announced an exclusive global licensing agreement enabling Seattle Genetics to …
Incyte (INCY) and Agenus (AGEN) announced an amendment of the License, Development and Commercialization Agreement that …
The FDA’s Center for Drug Evaluation and Research (CDER) informed Portola (PTLA) that it does not …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
